Who was studied, and how
Three numbers in the abstract
Where each one falls
Where it lands on the map
What it changes
Among 23 other studies
1,091people with type 2 diabetes, in this paper
The trial randomly assignedassigned by chance
1.8 mg liraglutide
placebo
Reported lower A1C values, no range given−1.00
randomisedThe trial randomly assignedassigned by chance
0.6 mg liraglutide
placebo
Reported lower A1C values, no range given−0.70
randomisedthe abstract, start to end
A1C values were significantly reduced in all liraglutide groups versus the placebo group (P < 0.0001) with mean decreases of 1.0% for 1.8 mg liraglutide, 1.2 mg liraglutide, and glimepiride and 0.7% for 0.6 mg liraglutide and an …
… decreased in all liraglutide groups (1.8-2.8 kg) compared with an increase …
← favours treatmentfavours comparator →
could be chanceNo interval given · direction only, strength unknown
A1C values1.8 mg liraglutide vs placebo
−1.00
A1C values0.6 mg liraglutide vs placebo
−0.70
Body weight1.8 mg liraglutide vs glimepiride
−2.80
GLP-1 receptor agonistsGlycemic controlBody weight & composition
GLP-1 receptor agonists × glycemic controlhelps?replicated
unlikelylikely
0.910.91 without it
← favours treatmentfavours comparator →
1 / 6